Bristol will get a nearly 20% stake in the startup, which will advance five drugs that no longer fit into its future immunology plans.Dive Brief:Bristol Myers Squibb and investment firm Bain Capital have joined forces to form a new biotechnology startup built around five of the pharmaceutical company’s experimental immune disease drugs.According to Bristol Myers, […]
